Randomised controlled trial
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease
- Randomised controlled trial
- multicentre
- non-inferiority
- 12 centres in South Korea
Authors' conclusion
Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization.
Study context
- Population
- Patients with CAD, South Korea, enrolled 2016–20194,341 (98.7%) completed
- Participants
- 4,400 patients
- Comparison
- Treat-to-target low-density lipoprotein cholesterol (LDL-C) strategy vs high-intensity statin
- Treat-to-targetn = 2,200
- High-intensity statinn = 2,200reference
- Primary endpoint
- Composite of:
- Death
- MI
- Stroke
- Coronary revascularization (non-inferiority margin 3.0 percentage points)
- Follow-up
- 3 years
Primary result
As reported in the abstract
Absolute difference
−0.6 percentage points
1-sided 97.5% CI upper boundary 1.1
P < 0.001 for non-inferiority
Events by treatment group
Further findings
Mean LDL-C over 3 years
P = 0.21
- Statin dosing in treat-to-target
- 43% · Moderate-intensity dosing · High-intensity dosing 54%
Original publication
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease. JAMA. Published 4 April 2023. doi:10.1001/jama.2023.2487
Summarised from the published abstract; every number is checked against it